1. Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
- Author
-
Shiqin Zhang, Kyongtae T. Bae, Vicente E. Torres, William M. Bennett, Douglas Landsittel, Frederic F. Rahbari-Oskoui, Jared J. Grantham, Jason R. Stubbs, Pengcheng Lu, Mireille El Ters, Jonathan D. Mahnken, Darren P. Wallace, Peter C. Harris, Michal Mrug, Alan S.L. Yu, and Arlene B. Chapman
- Subjects
Fibroblast growth factor 23 ,medicine.medical_specialty ,030232 urology & nephrology ,Urology ,Autosomal dominant polycystic kidney disease ,Renal function ,Kidney Volume ,030204 cardiovascular system & hematology ,lcsh:RC870-923 ,urologic and male genital diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Clinical Research ,FGF23 ,Medicine ,ADPKD ,Creatinine ,business.industry ,Hazard ratio ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,female genital diseases and pregnancy complications ,chemistry ,Quartile ,Nephrology ,Cohort ,business - Abstract
Introduction Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset of end-stage renal disease (ESRD) occur late in the disease course. There is therefore a great need for early prognostic biomarkers in this disorder. Methods We measured baseline serum fibroblast growth factor 23 (FGF23) levels in 192 patients with ADPKD from the Consortium for Radiologic Imaging Studies of PKD (CRISP) cohort that were followed for a median of 13 years and tested the association between FGF23 levels and change over time in height-adjusted total kidney volume (htTKV), GFR, and time to the composite endpoints of ESRD, death, and doubling of serum creatinine. Results Patients in the highest quartile for baseline FGF23 level had a higher rate of increase in htTKV (0.95% per year, P = 0.0016), and faster rate of decline in GFR (difference of −1.03 ml/min/1.73 m2 per year, P = 0.005) compared with the lowest quartile, after adjusting for other covariates, including htTKV and genotype. The highest quartile of FGF23 was also associated with a substantial increase in risk for the composite endpoint of ESRD, death, or doubling of serum creatinine (hazard ratio [HR] of 2.45 in the fully adjusted model, P = 0.03). Conclusion FGF23 is a prognostic biomarker for disease progression and clinically important outcomes in ADPKD, and has additive value to established imaging and genetic biomarkers., Graphical abstract
- Published
- 2021